Giant Bio: Subsidiary Obtains Registration Certificate for Cross-linked Recombinant Collagen Implant, containing 1068 amino acids.

Juzi Biology announced that its wholly-owned subsidiary, Shaanxi Juzi Biotechnology Co., Ltd., received today the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for the cross-linked recombinant collagen implant. This product uses the full-length sequence of human type III mature collagen protein, consisting of 1068 amino acids, fully preserving the natural functional domains of collagen protein. It adopts a physical cross-linking process without the risk of residual chemical cross-linking agents, and is used for injection filling in the dermis of the neck to correct moderate to severe horizontal lines in the neck. The product was included in the priority approval of medical devices by the National Medical Products Administration in December 2024, and is now the world's first cross-linked recombinant type III collagen filler for neck wrinkle filling.